JW (Cayman) Therapeutics Co. Ltd
藥明巨諾(開曼)有限公司

03 NOV 2020

Co-founded by Juno Therapeutics and Wuxi AppTec, JW (Cayman) Therapeutics Co. Ltd (the “Company”) is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. 

The Company’s vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. Relma-cel, an anti-CD19 CAR-T therapy for relapsed or refractory (“r/r”) B-cell lymphoma, is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China. The company has built a comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors.

藥明巨諾（開曼）有限公司（「公司」）是一家中國領先的臨床及臨床前階段細胞治療公司，由美國巨諾和藥明康德聯合創建，公司建立了一個專注為血液癌症及實體瘤開發、製造和商業化的突破性細胞免疫療法的一體化平台。

公司的願景是為中國市場開發創新的細胞治療手段，為中國癌症患者帶來革命性的新藥治療方式。Relma-cel是針對復發或難治（「r/r」）B細胞淋巴瘤的抗CD19 CAR-T療法，有望成為中國首個獲批一類生物製品CAR-T療法。公司已建立了涵蓋血液癌症及實體瘤的全面且差異化的細胞治療產品管線。